GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) (-)

Kawai Norisuke0 个研究点目标入组 2,000 人开始时间: 2020年12月25日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1.Medical history of heart failure (HF) with:
•a.At least 1 episode with clinical evidence of HF (without hospitalization) by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement; OR
•b.1 prior hospitalization for HF.
•2.Left ventricular ejection fraction (LVEF) >40%.
•3.End-diastolic interventricular septal wall thickness (IVST) >=12 mm.
•4.Willing and able to undergo scintigraphy.

•1.Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF <=40%).
•2.Prior clinical history of myocardial infarction, CABG or multi-vessel obstructive coronary disease (>50% stenosis of >=2 epicardial coronary arteries).
•3.Presence or history of any severe valvular heart disease (obstructive or regurgitant).
•4.A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known pericardial constriction.
•5.Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain] amyloidosis) or prior diagnosis of ATTR-CM.

发起方

Kawai Norisuke